The BST2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human SK-HEP-1 liver adenocarcinoma cell line. The BST2 gene was disrupted using CRISPR/Cas9, generating a heterogeneous pool of cells lacking functional tetherin protein. This polyclonal knockout model enables population-level studies of BST2-dependent phenotypes, avoiding clonal selection artifacts. Loss of BST2 abrogates both its viral tethering activity and its signaling scaffold functions.
The parental SK-HEP-1 cell line originates from the ascitic fluid of a male patient with liver adenocarcinoma. Characterized by loss of p53 and Rb tumor suppressor function, these cells are highly tumorigenic and widely employed to investigate hepatocellular carcinoma (HCC) biology, drug resistance, and metastasis. SK-HEP-1 exhibits mesenchymal features and retains endothelial-like properties, providing a clinically relevant system to study BST2??s role in HCC progression and immune evasion.
BST2 (tetherin/CD317) is a type II transmembrane GPI-anchored protein that restricts enveloped virus release by tethering virions to the plasma membrane. Beyond antiviral activity, BST2 functions as a signaling scaffold that activates NF-??B. Stimuli including interferon-alpha (IFN-??), TNF-??, and IL-6 promote BST2-dependent activation of the IKK complex, leading to NFKBIA degradation and RELA nuclear translocation, which induces transcription of target genes such as IL-6, IL-8, and MMPs. BST2 interacts with viral countermeasures (Vpu, Env, Nef) and cellular factors (LFA-1, GRP78, ezrin, moesin) that connect it to actin dynamics.
In SK-HEP-1 cells, BST2 knockout allows dissection of tetherin??s contribution to HCC-associated processes. Given that BST2 upregulation correlates with enhanced migration, invasion, and poor prognosis in several cancers, this model permits investigation of how BST2 loss affects NF-??B-driven inflammatory and metastatic gene programs. The SK-HEP-1 background, deficient in p53/Rb and with mesenchymal traits, is ideal for assessing BST2??s impact on tumor cell adhesion, cytoskeletal remodeling, and immune signaling pathways.
This knockout cell population supports virology studies using viral release assays (p24 or titer measurements) where BST2 restriction is eliminated. In cancer research, it facilitates transwell migration/invasion assays, NF-??B luciferase reporter assays, co-immunoprecipitation of BST2-binding partners, and rescue experiments. Standard techniques such as Western blotting, flow cytometry, and immunofluorescence validate knockout and downstream signaling. The model is also suitable for screening antiviral and anticancer agents targeting BST2-dependent pathways. For more information, contact Ascent Research.
